ArticleMacromolecular bioscience2025
Histidine Decapeptide-Incorporating Lipid Nanoparticles with Low Ionizable Lipids Proportion for Efficient Small Interfering RNA Delivery.
Article in Macromolecular bioscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Histidine Decapeptide-Incorporating Lipid Nanoparticles with Low Ionizable Lipids Proportion for Efficient Small Interfering RNA Delivery.Macromolecular bioscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The diversification of lipid compositions in lipid nanoparticles (LNPs) is crucial for expanding their clinical applications and overcoming current limitations. In this study, LNPs with varying lipid compositions are fabricated using three different mixing processes (pipette, vortex, and microfluidic mixing) for small interfering RNA (siRNA) delivery. While both siRNA and hydrophobic fluorescent dye are successfully incorporated within LNPs using pipette- and vortex-mixing, hydrophilic peptides cannot be encapsulated. Following optimization of ionizable lipid proportion via cost-efficient vortex-mixing method, LNPs with a lower ionizable lipid proportion (27.72%), termed LNP5, are selected and fabricated with histidine decapeptide (His10) during formulation via microfluidic mixing method to supplement the function of approximately half of the ionizable lipids by simple addition of His10. His10- incorporated LNP5 (LNP5H) exhibited a 1.6-fold increase in gene silencing efficiency, compared to conventional LNPs (cLNPs; ionizable lipid proportion of 47.95%). Furthermore, LNP5H maintained siRNA potency for 4 weeks when stored in a 1% sucrose solution at -70 °C. Taken together, it fabricates potent LNP5H with low proportion of ionizable lipids via fast and easy processes, which can be applied to a variety of siRNA therapeutics for their efficient intracellular delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.